Alivus Life Sciences Ltd (ALIVUS)
₹1,101.20
Mkt cap
₹13,516 Cr
P/E ratio
23.20
P/B
4.06
Div yield
0.45%
ROE
19.00%
ROCE
25.00%
EPS (TTM)
₹47.47
Book value
₹271
52W range
860–1,168
Sector
Healthcare
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−5.75% from high₹1,101
₹860+28.04% from low₹1,168
Current
₹1,101.20
Prev close
₹1,107.00
Day
−0.52%
Price performance
1D
−0.52%
1W
−2.75%
1M
−0.64%
3M
+4.87%
6M
+26.82%
1Y
+3.03%
YTD
+20.61%
Financials
FRevenue, profit & margin
P/E ratio
23.2×
ALIVUS is 32% below the sector median of 34.0×
ALIVUS23.2×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 621 | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | |
| Expenses | 415 | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | |
| Operating Profit | 206 | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | |
| OPM % | 33% | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | |
| Other Income | 3 | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 12 | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | |
| Profit before tax | 198 | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | |
| Tax % | 26% | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | |
| Net Profit | 146 | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | |
| EPS in Rs | 11.95 | 11.05 | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
30 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.43% · closed higher next day 9 of last 19
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 21 Jul '23◦ | 20 Oct '23◦ | 23 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24◦ | 24 Oct '24◦ | 23 Jan '25◦ | 15 May '25◦ | 1 Aug '25◦ | 6 Nov '25◦ | 22 Jan '26 | 14 May '26◦ |
| Earnings day | +0.09% | −0.75% | +1.18% | +8.59% | −2.92% | −9.86% | −1.52% | −5.26% | −3.49% | +2.76% | +0.02% | −1.83% |
| +1 day | −0.59% | −1.07% | +5.82% | +9.15% | −0.63% | −5.95% | +2.62% | −5.10% | −1.39% | +3.38% | +2.58% | −0.83% |
| +5 days | +5.64% | +0.20% | +8.42% | +10.72% | +0.88% | +3.11% | +2.85% | −7.38% | −7.32% | +1.59% | +11.58% | −2.36% |
| +15 days | +1.60% | +1.11% | +10.82% | +9.60% | +13.46% | +4.02% | −12.07% | −16.58% | −5.21% | +0.90% | +6.79% | −5.84% |
| +30 days | −0.62% | +1.84% | −3.13% | +16.79% | +37.51% | +0.85% | −7.54% | −16.97% | −6.16% | +1.14% | +6.79% | +8.68% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202674.87%Promoter
Promoters74.87%
FIIs5.54%0.24
DIIs7.18%0.09
Public12.42%0.13
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Alivus Life | ₹1,101.20 | 23.15 | 13,516 | 0.45% | 163 | +14.65% | 689 | +6.09% | 24.98% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports5
Concall transcripts44
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024PPTOct 2024RECOct 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptMay 2024PPTMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1d - Enclosed please find herewith the details of Earnings Call slated for Friday, July 31, 2026 from 8:30 a.m. to 9:30 a.m. (IST), for your information …Closure of Trading Window 1dBoard Meeting Intimation for Considering And Approving Unaudited Financial Results Of The Company For The Quarter Ended 30Th June, 2026. 1d - Board meeting on July 30, 2026 to approve Q1 FY27 unaudited financial results; trading window closed July 1-August 1.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Jun - Alivus Life Sciences will host institutional investors for a plant visit in Ankleshwar on June 29, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Jun - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Analyst / Institutional Investor Meeting.